PATENT CLAIM ANALYSIS

Application Number: 15870355
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "394000"]

Abstract:
The present invention provides a method for treating a disease or condition in a mammal which comprises the steps of; administering a therapeutically effective amount of a T type calcium channel inhibitor to effectively slow or stop progression of eukaryotic cells through the S, G 2  and M phases of the cell cycle to increase the proportion of the eukaryotic cells in the G 1  phase, stopping administration of the T type calcium channel inhibitor for a period of time, and administering a dosage selected from the group consisting of a dosage of at least one chemotherapeutic agent, a dosage of radiation, and combinations thereof, to kill the proportion of eukaryotic cells progressing past the G 1  phase of the cell cycle after the stopping of the administration of the T type calcium channel inhibitor.

Claim (Index 32):
The method of  claim 22 , wherein said S phase cytotoxin is administering at a dose of 25% of an LDio of said S phase cytotoxin.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 86.0
- Lexical Diversity: 2.01408
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13581390', '11908416', '10284490', '11334160', '15331478']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7337267081898184
- 35 USC 102 Novelty (BERT): 0.5038102763099546
- Combined Prediction Score: 0.7107350650018321
- Mean Citation Score: 173.918346
- Max Citation Score: 226.52165
- Similarity Product: 149.54184328660963

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test